Cartesian Therapeutics (RNAC) EBITDA Margin (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly EBITDA Margin came in at 33973.08% in Q1 2026, down 3198317.0% year-on-year from N/an in Q1 2025, and down 309.12% on a QoQ basis from 8304.01% in Q4 2025.
Cartesian Therapeutics (RNAC) EBITDA Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of EBITDA Margin data on file, last reported at 33973.08% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 3198317.0% year-over-year to 33973.08% in Q1 2026; TTM through Mar 2026 was 14440.49%, a 1428412.0% decrease from a year earlier, with the FY2025 full-year figure at 5127.1%, down 501241.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 33973.08%, down from 8304.01% in the prior quarter.
- Over the last five years, EBITDA Margin for RNAC reached as high as 3197.49% in Q4 2024 and fell as low as 33973.08% in Q1 2026.
- Historically, EBITDA Margin has averaged 3039.4% across 5 years, with a median of 214.0% in 2024.
- Across the five-year window, EBITDA Margin soared 363702 bps in 2024 and tumbled 3198317 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 50.59% in 2022, then slumped by 769 bps to 439.54% in 2023, then soared by 827 bps to 3197.49% in 2024, then sank by 360 bps to 8304.01% in 2025, then sank by 309 bps to 33973.08% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 33973.08% in Q1 2026, 8304.01% in Q4 2025, and 1989.91% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Cartesian Therapeutics | 210.28 Mn | 210.28 Mn | - | -33,973.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,973.08% |
| Dec 31, 2025 | -8,304.01% |
| Mar 31, 2025 | -1,989.91% |
| Dec 31, 2024 | 3,197.49% |
| Jun 30, 2024 | 41.35% |
| Mar 31, 2024 | -228.56% |
| Dec 31, 2023 | -439.54% |
| Sep 30, 2023 | -199.44% |
| Jun 30, 2023 | -355.08% |
| Mar 31, 2023 | -309.55% |
| Dec 31, 2022 | -50.59% |
| Sep 30, 2022 | -7.72% |
| Jun 30, 2022 | 35.29% |
| Mar 31, 2022 | 31.69% |
| Dec 31, 2021 | 13.62% |
| Sep 30, 2021 | -8.06% |
| Jun 30, 2021 | 2.30% |
| Mar 31, 2021 | -64.78% |
| Dec 31, 2020 | -66.09% |
| Sep 30, 2020 | -295.61% |